scholarly journals Are topical keratolytic agents needed in the treatment of scalp psoriasis?

2014 ◽  
Vol 20 (3) ◽  
Author(s):  
Divya Shokeen ◽  
Jenna L O'Neill ◽  
Arash Taheri ◽  
Scott R Feldman
Keyword(s):  
Scalp Psoriasis ◽  
Keratolytic Agents

Ixekizumab in the Management of Non-Selected Out Patients with Moderate to Severe Psoriasis -New Data and Personal Clinical Experience

2018 ◽  
Vol 3 (3) ◽  
Keyword(s):  
Clinical Experience ◽  
Personal Experience ◽  
Therapeutic Response ◽  
Systemic Disease ◽  
Severe Psoriasis ◽  
Adequate Treatment ◽  
Scalp Psoriasis ◽  
Number Of Patients ◽  
Genital Psoriasis

Introduction: Too many patients with moderate to severe psoriasis do not receive adequate treatment. This means a vast undersupply in the treatment of patients with psoriasis. Only biologics fulfill the whole range of the treatment of psoriasis – psoriasis does not affect only skin but the whole organism: It is a systemic disease! Between the biologics are evident differences concerning the effect. Discussion: Based on broad personal experience in the management of patients with moderate to severe psoriasis new data from clinical studies with ixekizumab are examined. This contains new data on long-term-efficacy of ixekizumab, effectiveness in special localizations (scalp psoriasis, nail psoriasis, palmoplantar psoriasis, genital psoriasis) as well as safely data and experience on patients switched to ixekizumab from other biologics. Personal clinical experience is based on >300 non-selected outpatients with moderate to severe psoriasis, >250 patients on biological therapies, > 50 patients with ixekizumab. Conclusions: Focusing on a relevant number of patients switched from secukinumab to ixekizumab due to first or secondary loss of efficacy significant differences between both IL-17A-inhibitors mainly in terms of efficacy and speed of therapeutic response are shown. Finally the correlation between PASI-90-/PASI-100 response and significant changes in DLQI are highlighted.

Efficacy and safety of 308‐nm excimer lamp in the treatment of scalp psoriasis: a retrospective study

2019 ◽  
Vol 35 (3) ◽  
pp. 172-177
Author(s):  
Ploysyne Rattanakaemakorn ◽  
Phanitchanat Phusuphitchayanan ◽  
Kallapan Pakornphadungsit ◽  
Kunlawat Thadanipon ◽  
Poonkiat Suchonwanit
Keyword(s):  
Retrospective Study ◽  
Efficacy And Safety ◽  
Excimer Lamp ◽  
Scalp Psoriasis

scholarly journals Characteristics of Pruritus in Various Clinical Variants of Psoriasis: Results of the Multinational, Multicenter, Cross-Sectional Study

Life ◽  
2021 ◽  
Vol 11 (7) ◽  
pp. 623
Author(s):  
Kamila Jaworecka ◽  
Dominika Kwiatkowska ◽  
Luiza Marek ◽  
Funda Tamer ◽  
Aleksandra Stefaniak ◽  
...  
Keyword(s):  
Clinical Symptoms ◽  
Cross Sectional Study ◽  
Pustular Psoriasis ◽  
Cross Sectional ◽  
Large Plaque ◽  
Scalp Psoriasis ◽  
Generalized Pustular Psoriasis ◽  
Itch Sensation ◽  
Clinical Variants ◽  
Subtype A

Psoriasis is a chronic, inflammatory skin disease present in about 3% of the world’s population. The clinical symptoms manifest diversely, therefore one can distinguish several subtypes of psoriasis. The majority of patients with psoriasis experience pruritus, which is an unpleasant sensation that decreases patients’ quality of life. The knowledge on pruritus in different subtypes of psoriasis is limited. We have performed a cross-sectional, prospective, and multicenter study to evaluate the relationship between clinical subtypes of psoriasis (large-plaque, nummular, guttate, palmoplantar, inverse, erythrodermic, palmoplantar pustular, generalized pustular psoriasis, and psoriasis of the scalp) and the prevalence, intensity, and clinical manifestation of itch. We introduced a questionnaire assessing various aspects of pruritus to a total of 254 patients. Out of these, 42 were excluded. Pruritus was present in 92.9% of the remaining patients and its prevalence did not depend on the clinical subtype. A correlation between the severity of psoriasis and the intensity of itch was explicitly noticeable in palmoplantar pustular psoriasis and scalp psoriasis (p < 0.05). The itch sensation was individual and differed among subtypes of psoriasis. In conclusion, pruritus is a frequent phenomenon, and its presentation is different in various subtypes of psoriasis.

Cost effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of scalp psoriasis in Scotland

2010 ◽  
Vol 27 (1) ◽  
pp. 269-284 ◽  
Author(s):  
Andrew G. Affleck ◽  
Julia M. Bottomley ◽  
Merran Auland ◽  
Peter Jackson ◽  
Jacob Ryttov
Keyword(s):  
Cost Effectiveness ◽  
Betamethasone Dipropionate ◽  
Scalp Psoriasis

scholarly journals Scalp Psoriasis: A Brief Overview

2016 ◽  
Vol 2 (2) ◽  
Author(s):  
Meghana Madhukar Phiske
Keyword(s):  
Scalp Psoriasis

Teratogenic Potential of Isotretinoin

1986 ◽  
Vol 8 (3) ◽  
pp. 68-94
Keyword(s):  
Animal Models ◽  
Vitamin A ◽  
Premature Infant ◽  
Congenital Anomalies ◽  
Pharmacologic Therapy ◽  
Multiple Congenital Anomalies ◽  
Keratolytic Agents ◽  
Teratogenic Potential ◽  
Vitamin A Derivative ◽  
Systemic Antibiotics

Pharmacologic therapy for acne, for the most part, consists of topical keratolytic agents and systemic antibiotics, but these modalities have had very little success in the treatment of cystic acne. In September 1982, isotretinoin, a Vitamin A derivative, was marketed for the treatment of recalcitrant acne and has proven to be efficacious. Because of the known teratogenicity of vitamin A in animal models, a manufacturer's warning was issued advising patients not to take this medication if they were pregnant or intended to become pregnant. Despite these warnings, there are reported cases of multiple congenital anomalies in infants born to mothers who took isotretinoin during the first half of pregnancy. Among the reported cases is a premature infant of 30 weeks' gestation born to a 22-year-old woman who used isotretinoin during her first 2 months of pregnancy.

scholarly journals Management of scalp psoriasis: current perspectives

2016 ◽  
pp. 33
Author(s):  
Melinda Gooderham ◽  
Kim Blakely
Keyword(s):  
Scalp Psoriasis
Sign in / Sign up

Export Citation Format

Share Document